Welcome to the PROteKT Trial Website  

PROteKT is a Phase IIa, Randomised, Controlled, Open-Label Trial of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in Children with Cystic Fibrosis

Trial Sponsor: University of Liverpool.

Trial Funders: The J P Moulton Charitable Foundation and the North West England MRC Clinical Pharmacology and Therapeutic Fellowship awarded to Dr S McWilliam.

Trial Coordination: The University of Liverpool Clinical Trials Research Centre (data management and statistics) and the University College of London (trial management).


I'm fine with this [X]

The site uses cookies, some may have been set already. Please refer to our privacy policy & cookie usage statement.
If you continue to use the site we'll assume you're happy to accept the cookies.